OLD Category: signatures

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

• Omarini C. et. al.,

Reduction of measurement noise in a continuous glucose monitor by coating the sensor with a zwitterionic polymer

• Xie X et al.,

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

• de Vos S. et. al.,

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

• Jensen M-B. et. al.,

In vivo identification of Bmp2-correlation networks during fracture healing by means of a limb-specific conditional inactivation of Bmp2

• Yu YH et al.,

Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma

• Zhang XH, Nam S, Wu J, Chen CH, Liu X, Li H, McKeithan T, Gong Q, Chan WC, Yin HH, Yuan YC, Pillai R, Querfeld C, Horne D, Chen Y, Rosen ST.

A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology

• Michelsen T.Y. et. al.,

Hematopoietic cell-derived RELMα regulates hookworm immunity through effects on macrophages

• Batugedara HM et al.,

Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant

• Rosko A.E. et. al.,

A B-cell–associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology

• Michaelsen T.Y. et. al.,

BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy

• Conteduca V et al.,

More than Fishing for a Cure: The Promises and Pitfalls of High Throughput Cancer Cell Line Screens

• Ling A et al.,